The study found a 20% reduction in dementia risk among SGLT2 inhibitor users (adjusted hazard ratio [aHR]: 0.80, 95% CI: 0.71–0.89), with dapagliflozin showing the most significant neuroprotective effect [53]. Here, SLC5A2 is linked to dementia.